Abstract
Abstract 11966: The Real-Life Differences Between the Use of Ticagrelor and Clopidogrel in ST-Elevation Myocardial Infarction
Circulation (New York, N.Y.), Vol.138(Suppl_1 Suppl 1), pp.A11966-A11966
11/06/2018
Abstract
IntroductionThe preference of the use of ticagrelor versus clopidogrel in patients with ST elevation myocardial infarction (STEMI) is based mainly on many inconclusive results and sub-analyses of many clinical trials and few data is available on the real-life effects of ticagrelor after many years of application. The aim of this study is to compare the effects of ticagrelor and clopidogrel in a real-life STEMI population regarding the evidence of early reperfusion before primary percutaneous coronary intervention (PPCI) as well as reperfusion success after PPCI and the need to use glycoprotein IIb/IIIa inhibitors after PPCI.HypothesisWe hypothesize that ticagrelor has higher early reperfusion rate in comparison to clopidogrel.MethodsA retrospective study based on the analysis of the data of 369 STEMI patients admitted in the period from January 2014 till December 2017 was done. The patients were divided into 2 groups, the clopidogrel group consisted of 198 patients who received an initial loading dose of clopidogrel 600 mg followed by 75 mg once daily and the ticagrelor group that consisted of 171 patients who received initial loading dose of ticagrelor 180 mg followed by 90 mg twice daily.ResultsComparing the two groups regarding the demographic data, risk factors, past history, clinical examination and laboratory data, there was no significant difference between the two groups. Regarding early perfusion before PPCI represented by TIMI II-III flow, there was a significant difference between the two groups (51.5% in ticagrelor group Vs 28.3% in clopidogrel group, P = 0.041). Regarding the use of glycoprotein IIb/IIIa inhibitors, there was no significant difference between the two groups. Regarding the in-hospital all cause death and in-hospital cardiovascular death, there was a significant difference between the two groups (0.6% in ticagrelor group Vs 4.5% in clopidogrel group, P = 0.022 and 0.6% ticagrelor group Vs 4% in clopidogrel group, P = 0.049) respectively.ConclusionsIn the setting of STEMI, the use of ticagrelor rather than clopidogrel was associated with improved early perfusion assessed by TIMI flow before PPCI and a lower incidence of in-hospital cardiovascular and all-cause mortality after PPCI.
Details
- Title: Subtitle
- Abstract 11966: The Real-Life Differences Between the Use of Ticagrelor and Clopidogrel in ST-Elevation Myocardial Infarction
- Creators
- Abdallah Almaghraby - Alexandria UniversityYehia Saleh - Michigan State UniversityMahmoud Abdelnaby - Alexandria UniversityOla Abdelkarim - Alexandria UniversityHaitham Badran - Ain Shams University
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.138(Suppl_1 Suppl 1), pp.A11966-A11966
- Publisher
- by the American College of Cardiology Foundation and the American Heart Association, Inc
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/06/2018
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984757271102771
Metrics
1 Record Views